Uncovering the influence of the FGFR1 pathway on glioblastoma radiosensitivity

Gliomas are the most frequently occurring brain tumour, of which glioblastomas (WHO grade IV gliomas) are the most common subtype and carry a particularly poor prognosis, leading to 5-year survival rates of just 9.8% (1,2). Radiation is an effective treatment modality although dose escalation is limited by the narrow therapeutic index. Consequently, there is a clear and unmet clinical need for effective radiosensitisation strategies for glioblastoma which enhance anti-tumour efficacy without increasing dose-limiting normal tissue toxicity. The paucity of effective clinically validated radiosensitisers further highlights the need for novel therapeutic targets for radiosensitisation of glioblastoma.